United States· US:72060-142_fa0963da-0db0-41f8-bb1a-153908a8bd77
CAPLYTA
A lumateperone product containing lumateperone, registered in United States by Intra-Cellular Therapies, Inc.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- LUMATEPERONE
- Manufacturer
- Intra-Cellular Therapies, Inc
- Country
- United States (US)
- ATC code
- N05AD10
- ATC class
- Lumateperone
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1172060142077 CAPSULE in 1 BOTTLE (72060-142-07)
- ndc11720601424030 CAPSULE in 1 BOTTLE (72060-142-40)
- ndc1172060-142-07
- ndc1172060-142-40
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
238 interactions on record for lumateperone.
Graded by severity as the source publishes them — 59 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lumateperone · interactions on record
238 records
- 59 severe
- 179 moderate
Most severe, free to view
- MetoclopramideA03FA01severe
- AprepitantA04AD12severe
- PrednisoneA07EA03severe
- TroglitazoneA10BG01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under N05AD10
Lumateperone, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c36d3ca3-391d-42fd-bfd9-d4db59a4aea7 GET /v1/drugs/c36d3ca3-391d-42fd-bfd9-d4db59a4aea7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "42",
"substance": "LUMATEPERONE",
"productndc": "72060-142",
"dosage_form": "CAPSULE",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA209500",
"marketing_category": "NDA"
}See everything about lumateperone.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.